# Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs

> **NCT01033552** · PHASE1,PHASE2 · COMPLETED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 32 (actual)

## Conditions studied

- Epidermolysis Bullosa

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Anti-thymocyte globulin
- **DRUG:** Myeloablative Busulfan
- **PROCEDURE:** Mesenchymal stem cell transplantation
- **RADIATION:** Total body irradiation
- **PROCEDURE:** Bone marrow or umbilical cord blood (UCG) stem cell transplantation

## Key facts

- **NCT ID:** NCT01033552
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2021-08-12
- **Final completion:** 2021-08-12
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01033552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01033552, "Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01033552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*